Bruce brings a proven track record of success in strategic acquisitions and in raising debt and equity finance. An accountant by training, Bruce Pritchard, BA, CA, FioD has spent over two decades working in the life sciences and pharmaceutical industry. Bruce was appointed CEO of Caledon Bioscience Inc. in October 2023 and has more than sixteen years’ experience with Liminal BioSciences Inc. having held a number of senior global positions across the organisation. As well as being a chartered accountant, Bruce also brought to the role many years of experience in general management and operations. Prior to joining Liminal, Bruce worked as a senior director for CV Therapeutics, a NASDAQ listed biopharmaceutical company. Bruce is a graduate of Heriot-Watt University where he gained a BA in Accountancy and Computer Science. He is a member of the Institute of Chartered Accountants of Scotland and a Fellow of the Institute of Directors. He is also Chair of Court at Heriot-Watt University, Interim Board Chair and Non-Executive Director of Porton Biopharma Limited and is a Past President of The Institute of Chartered Accountants of Scotland.